Calendar Year Performance 2015Calendar Year Performance 2016Calendar Year Performance 2017Calendar Year Performance 2018Calendar Year Performance 2019Calendar Year Performance 2020Calendar Year Performance 2021Calendar Year Performance 2022Calendar Year Performance 2023Calendar Year Performance 2024
- 1.4 %
+ 5.1 %
+ 10.4 %
- 9.6 %
+ 34.8 %
+ 14.5 %
+ 21.7 %
- 21.1 %
+ 14.8 %
+ 11.3 %
Net Asset Value
309.45 €
Asset Under Management
670 M €
Net Equity Exposure31/03/2025
94.8 %
SFDR - Fund Classification
Article
9
Data as of: Apr 11, 2025.
Data as of: Apr 17, 2025.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged. The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to https://eur-lex.europa.eu/eli/reg/2019/2088/oj.
In March, European markets experienced a challenging period, with indices declining by 4%, particularly in economically sensitive sectors such as Industrials, Chemicals, Technology, and Healthcare.
Germany's fiscal stimulus measures, including a €500 billion infrastructure investment fund, provided substantial support to European markets.
However, the market narrative was dominated by tariff developments, with auto tariffs being confirmed in the last week of the month. Additionally, the market is preparing for the possibility of further tariffs from the Trump administration.
We expect these developments to act as a pivotal moment for the market, especially for stocks with significant international exposure and sales.
Performance commentary
In March, the fund registered a negative performance in both absolute and relative terms.
This underperformance was primarily driven by a notable shift in investor sentiment from growth stocks.
Our selection of stocks in the Financials sector contributed positively to the fund's performance. Notably, Deutsche Börse and Euronext demonstrated resilience to market volatility and performed well during the month.
However, the main detractors were stocks in the Healthcare and Information Technology sectors.
Novo Nordisk was the biggest detractor, as the growth rate for its obesity drug stalled, fuelling investor concerns about its sales guidance during the Q1 results.
Outlook strategy
During the month, we made some adjustments to our portfolio by initiating a new position in the Fund.
Throughout the month, we continued to enhance our exposure to Industrials by increasing our holdings in Schneider Electric but also Prysmian and Kingspan, which we recently initiated.
We started a small position in IMCD, a high-quality chemical distribution company that we have previously owned.
The stock has significantly derated in recent years due to rising bond yields, and we anticipate it will perform well in the current market environment.
Conversely, we reduced our positions in Euronext, Deutsche Börse, and Elis, which have performed well recently.
The Fund continues to rely on bottom-up fundamental analysis with a medium-long term horizon.
We continue to stick to our philosophy and believe that this is a great opportunity for our investors to gain access to a range of Europe’s best companies at attractive entry valuations.
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
Carmignac Portfolio is a sub-fund of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor), where applicable. Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.). The reference to a ranking or prize, is no guarantee of the future results of the UCITS or the manager.
Unsupported browserWe've noticed that your browser is no longer supported. To ensure optimal performance and security while using our website, we recommend updating your browser or other relevant software. Thank you for your understanding!
Market environment